Cumberland pharmaceuticals reports 11.6% fourth quarter 2024 revenue growth

2024 highlights include expanded product labeling, key fda designations and new study publications recent developments include phase 2 dmd study breakthrough results and vibativ china approval  nashville, tenn. , march 4, 2025 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company, announced today that its product portfolio of fda-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period.
CPIX Ratings Summary
CPIX Quant Ranking